The U.S. FDA granted accelerated approval to Modeyso for patients with diffuse midline glioma with an H3 K27M mutation with progressive disease. The U.S. Food and Drug Administration (FDA) has granted ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback